Immunovant, Inc is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
All Other Basic Organic Chemical Manufacturing (325199)
Pharmaceutical Preparations (2834)
Tom Dorney, MS, MBA
320 W 37th Street
New York, NY 10018